At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 48 enrolled
Drug / intervention
Entecavir +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b/2a Randomized, Open-label Clinical Trial of Daily Myrcludex B Versus Entecavir in Patients With HBeAg Negative Chronic Hepatitis B
In Brief
A Phase 2 clinical trial evaluating Entecavir and Myrcludex B for Chronic Hepatitis B. Completed, enrolled 48 participants across 9 sites.
Detailed Summary
A randomized, open-label multicentre clinical trial of daily Myrcludex B versus entecavir in patients with HBeAg negative chronic hepatitis B.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis B
CountriesRussia
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2012
Primary CompletionOct 2014
First PostedAug 2016
TodayJul 2026
First PostedAug 26, 2016
Enrollment StartNov 14, 2012
Primary CompletionOct 4, 2014
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 9.8 years ago
Interventions
Entecavirdrug
Myrcludex Bdrug